Partner/Investor Opportunities

To help us achieve the greatest impact for patients,
Pio Tx welcomes opportunities for partnering and collaborative discussions.

Current status of PIO-001 program:

  • PIO-001 specificity and epitope has been validated
  • In vitro functional assays have been developed and validated
  • Clear understanding of the biology and mechanism of action of the antibody has been achieved
  • High quality and differentiated reagents, assays, and models have been developed
  • Toxicology and regulatory paths to IND are clear
  • Engineering of PIO-001 into a final therapeutic candidate is currently being performed
  • Biomarker strategy and accompanying assays are being developed
  • Robust IP portfolio

Further information is available under confidential terms.

Pio Tx is taking this bold new discovery to market, and is collaborating with investors, the scientific community and immunology experts to bring this idea to life.